Eli Lilly Beats Quarterly Estimates as Weight-Loss Drug Sales Surge

The provided sources offer overwhelming and consistent evidence supporting both parts of the statement. The assessment is based on the following:1. **Exceeding Market Estimates:** Multiple high-authority news sources (CNBC, BNN Bloomberg, RTTNews) explicitly report that Eli Lilly's fourth-quarter earnings and revenue surpassed market estimates. This directly confirms the first part of the statement.2. **Attribution to Weight-Loss Drugs:** This crucial point is corroborated by the most authoritative sources available—primary documents from Eli Lilly itself. The official earnings press releases and investor presentations directly attribute the strong financial performance and significant revenue increase to the sales volume growth and momentum of its key drugs, Mounjaro and Zepbound, which are widely known for their use in weight loss. The financial workbook provides the specific sales data to substantiate this claim.3. **Consistency and Authority:** There are no contradictions among the sources. The primary source documents from the company (press releases, SEC filing portals, financial data) align perfectly with the reporting from credible secondary sources (CNBC, Yahoo Finance). The high authority and relevance scores of the sources further bolster confidence in their accuracy.In summary, the evidence directly from Eli Lilly and corroborated by major financial news outlets confirms that the company beat financial estimates and that this success was driven by sales of its weight-loss and diabetes drugs.